利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.021 秒)

    Methods for the administration of amifostine and related compounds
    1.
    发明授权
    Methods for the administration of amifostine and related compounds 有权
    氨磷汀和相关化合物的给药方法

    公开(公告)号：US06218377B1

    公开(公告)日：2001-04-17

    申请号：US09586753

    申请日：2000-06-05

    申请人： Martin Stogniew ,  Philip S. Schein

    发明人： Martin Stogniew ,  Philip S. Schein

    IPC分类号： A01N5700

    CPC分类号： A61K31/661 ,  A61K31/145 ,  A61K45/06

    摘要： The present invention provides methods of administering aminoalkyl phosphorothioate and/or aminoalkyl thiol compounds to patients in a manner that significantly reduces or decreases the adverse or undesirable side-effects of the compounds as compared with conventional intravenous administration.

    摘要翻译： 本发明提供了向患者施用氨基烷基硫代磷酸酯和/或氨基烷基硫醇化合物的方法，其与常规静脉内给药相比显着降低或降低了化合物的不良或不良副作用。

    Suppression of HIV expression by organic thiophosphate
    2.
    发明授权
    Suppression of HIV expression by organic thiophosphate 失效
    有机硫代磷酸盐抑制HIV表达

    公开(公告)号：US5824664A

    公开(公告)日：1998-10-20

    申请号：US37633

    申请日：1993-03-26

    申请人： Philip S. Schein ,  Thea Kalebic

    发明人： Philip S. Schein ,  Thea Kalebic

    IPC分类号： A61K31/66 ,  A01N57/10 ,  A01N57/00 ,  A61K31/13

    CPC分类号： A61K31/66 ,  A61K31/70

    摘要： Chronic HIV infection is treated by administering to a subject an organic thiophosphate alone or in combination with another anti-HIV or anti-AIDS drug. The organic thiophosphate is preferably WR 151327, a compound with antioxidant and free radical scavenging activities, or a functional derivative or analogue thereof. WR 151327 suppresses induction of HIV expression in chronically infected cells mediated by cytokines such as TNF.alpha. and GM-CSF. Pharmaceutical compositions comprising at least one organic thiophosphate in combination with one or more anti-HIV or anti-AIDS drugs are also disclosed.

    摘要翻译： 通过向受试者单独或与另一种抗艾滋病毒或抗艾滋病药物组合施用有机硫代磷酸盐来治疗慢性HIV感染。 有机硫代磷酸酯优选为WR 151327，具有抗氧化和自由基清除活性的化合物或其功能衍生物或类似物。 WR 151327抑制由细胞因子如TNFα和GM-CSF介导的慢性感染细胞中的HIV表达的诱导。 还公开了包含至少一种有机硫代磷酸酯与一种或多种抗艾滋病毒或抗艾滋病药物组合的药物组合物。

    Method of reducing chemotherapy toxicity using (methylaminopropylamino)propyl dihydrogen phosphorothioate
    6.
    发明授权
    Method of reducing chemotherapy toxicity using (methylaminopropylamino)propyl dihydrogen phosphorothioate 失效
    （甲基氨基丙基氨基）丙基二硫代磷酸酯降低化疗毒性的方法

    公开(公告)号：US5292497A

    公开(公告)日：1994-03-08

    申请号：US39690

    申请日：1993-03-29

    申请人： Philip S. Schein ,  James R. Piper

    发明人： Philip S. Schein ,  James R. Piper

    IPC分类号： A61K31/66 ,  A61K49/00 ,  A61K31/44 ,  A61K31/54 ,  A61K31/685

    CPC分类号： A61K31/66 ,  Y10S514/917 ,  Y10S514/922

    摘要： A method of decreasing the toxicity of chemical therapeutic agents administered in cancer chemotherapy including adminstration to a patient undergoing chemotherapy. This reduction in toxicity can be accomplished by administering an effective amount of S-3-(3-methylaminopropylamino)propyl dihydrogen phosphorothioate. Methods of inducing mucolytic activity and reducing toxicity of acetominophen overdose are also discussed. Such activities are induced through the administration of S-3-(3-methylaminopropylamino)propyl dihydrogen phosphorothioate.

    摘要翻译： 一种降低化学治疗剂在癌症化学疗法中的毒性的方法，包括给予经历化疗的患者。 这种毒性的降低可以通过施用有效量的S-3-（3-甲基氨基丙基氨基）丙基二硫代磷酸酯来实现。 还讨论了诱导醋酸布洛芬过量的粘液分解活性和降低毒性的方法。 通过施用S-3-（3-甲基氨基丙基氨基）丙基二硫代磷酸酯诱导这些活性。

    Platinum pharmaceutical agents
    7.
    发明授权
    Platinum pharmaceutical agents 失效
    白金药剂

    公开(公告)号：US4946954A

    公开(公告)日：1990-08-07

    申请号：US301773

    申请日：1989-01-26

    申请人： Abdolhossen Talebian ,  Dianna C. Green ,  Philip S. Schein

    发明人： Abdolhossen Talebian ,  Dianna C. Green ,  Philip S. Schein

    IPC分类号： C07F15/00 ,  A61K31/28 ,  A61K31/282 ,  A61K31/70 ,  A61K31/7135 ,  A61P35/00 ,  C07H20060101 ,  C07H23/00

    CPC分类号： C07H23/00 ,  C07F15/0093

    摘要： Platinum compounds useful in the treatment of cancer are disclosed. Compositions containing these compounds and methods of using the same are also discussed. Compounds having the formula ##STR1## wherein n is 0 or 1 and when n is 1 R.sub.1 is H or C.sub.1 -C.sub.4 alkyl, R is non-substituted higher alkyl or mono or disaccharide or a derivative of a mono or disaccharide,when n is O, R.sub.1 is H or C.sub.1 -C.sub.4 alkyl, R is H, halogen, non-substituted C.sub.1 -.sub.20 alkyl, aryl, arlalkyloxy, mono or disaccharide, or a derivative of a mono or disaccharide,and R.sub.2 and R.sub.3 are selected from the group consisting of hydrogen, C.sub.1.sup.-4 alkyl or R.sub.2 and R.sub.3 or R.sub.2 and R.sub.3 together are linked to adjacent carbon atoms on a four, five or six membered ring structure, or R.sub.2 and R.sub.3 together form a fused or bicyclic ring with adjacent carbon atoms, or R.sub.2 and R.sub.3 together are a substituted or unsubstituted C.sub.1-5 alkylene group; with the proviso that R and R.sub.1 cannot both be hydrogen when n=0, or a pharmaceutically acceptable salt thereof, are particularly useful.

    摘要翻译： 公开了可用于治疗癌症的铂化合物。 还讨论了含有这些化合物的组合物及其使用方法。 具有式（I）的化合物其中n为0或1，当n为1时，R 1为H或C 1 -C 4烷基，R为未取代的高级烷基或单或二糖或单糖或二糖衍生物， 当n为O时，R 1为H或C 1 -C 4烷基，R为H，卤素，未取代的C 1-20烷基，芳基，芳烷氧基，单或二糖或单糖或二糖衍生物，R2和R3为 选自氢，C 1-4烷基或R 2，并且R 3或R 2和R 3一起连接到四个，五个或六元环结构上的相邻碳原子，或者R 2和R 3一起形成稠合或双环， 相邻的碳原子，或者R 2和R 3一起是取代或未取代的C 1-5亚烷基; 条件是当n = 0时，R和R 1不能都是氢，或其药学上可接受的盐是特别有用的。

    Platinum pharmaceuticals
    8.
    发明授权
    Platinum pharmaceuticals 失效
    白金制药

    公开(公告)号：US4895936A

    公开(公告)日：1990-01-23

    申请号：US143761

    申请日：1988-01-14

    申请人： Abdolhossen Talebian ,  Dianna C. Green ,  Philip S. Schein

    发明人： Abdolhossen Talebian ,  Dianna C. Green ,  Philip S. Schein

    IPC分类号： C07F15/00 ,  C07H23/00

    CPC分类号： C07H23/00 ,  C07F15/0093

    摘要： Platinum compounds useful in the treatment of cancer are disclosed. Compositions containing these compounds and methods of using the same are also discussed. The compound have the formula: ##STR1## wherein n is 0 or 1, R.sub.1 is selected from the group consisting of hydrogen, a mono or disaccharide or a derivative thereof linked to the nitrogen atom by a --NHCO-amide moiety, an --NHCS-- thioamide moeity or a --CO-- carbonylmoiety, R' is selected from the group consisting of hydrogen and C.sub.1-4 alkyl, and R.sub.2 and R.sub.3 are selected from the group consisting of hydrogen, C.sub.1-4 alkyl or R.sub.2 and R.sub.3 or R.sub.2 and R.sub.3 together are linked to adjacent carbon atoms on a four, five or six membered ring structure, or R.sub.2 and R.sub.3 together form a fused or bicyclic ring with adjacent carbon atoms; with the proviso that R' and R.sub.1 cannot both be hydrogen when n=o,or a pharmaceutically acceptable salt thereof.

    摘要翻译： 公开了可用于治疗癌症的铂化合物。 还讨论了含有这些化合物的组合物及其使用方法。 该化合物具有下式：其中n为0或1，R1选自氢，一或二糖或其通过-NHCO-酰胺部分与氮原子连接的衍生物，-NHCS - 硫代酰胺或-CO-羰基，R'选自氢和C 1-4烷基，R 2和R 3选自氢，C 1-4烷基或R 2和R 3或R 2，和 R3一起连接到四个，五个或六元环结构上的相邻碳原子，或者R2和R3一起形成具有相邻碳原子的稠环或双环; 条件是当n = o时，R'和R 1不能都是氢，或其药学上可接受的盐。

    Galactose-C-6 nitrogen mustard compounds and their uses
    9.
    发明授权
    Galactose-C-6 nitrogen mustard compounds and their uses 失效
    半乳糖-C-6氮芥化合物及其用途

    公开(公告)号：US4656159A

    公开(公告)日：1987-04-07

    申请号：US666904

    申请日：1984-10-31

    申请人： Eugene McPherson ,  Philip S. Schein

    发明人： Eugene McPherson ,  Philip S. Schein

    IPC分类号： C12N5/06 ,  A61K31/70 ,  A61K31/7008 ,  A61K31/7024 ,  A61K31/7028 ,  A61P35/00 ,  A61P35/02 ,  C07H5/06 ,  C07H9/02 ,  C07H9/04 ,  C07H13/04 ,  C07H15/12

    CPC分类号： C07H9/04 ,  C07H15/12

    摘要： Compounds of the formula ##STR1## wherein X is halogen; each R independently represents H, a C.sub.1 -C.sub.4 alkyl group, a C.sub.2 -C.sub.4 alkanoyl group, a phosphate group, or a sulfate, sulfonate, or benzoate group with the proviso that no more than one sulfate, sulfonate, or benzoate group is present in said compound; and R' represents R or a carbohydrate residue derived from a carbohydrate having the formula R'OH with the proviso that R' and the R on C-2 or both R groups on C-3 and C-4 together can represent an isopropylidene group; or a pharmaceutically acceptable salt thereof, are disclosed along with methods of synthesizing and using these compounds.

    摘要翻译： 式（Ⅰ）化合物，其中X是卤素; 每个R独立地表示H，C1-C4烷基，C2-C4烷酰基，磷酸基或硫酸根，磺酸根或苯甲酸根，条件是不超过一个硫酸根，磺酸根或苯甲酸根存在 在所述化合物中; 并且R'表示R或衍生自具有式R'OH的碳水化合物的碳水化合物残基，条件是R'和C-2上的R或C-3和C-4上的两个R基团可以一起代表异丙叉基 ; 或其药学上可接受的盐以及合成和使用这些化合物的方法。